Pharmalucence Builds New Drug Production Facility in Massachusetts
06/04/2010
"Pharmalucence has long maintained a strong radiopharmaceutical business in Massachusetts," said Glenn Alto, president and CEO of Pharmalucence. "We are investing to fully replace and modernize our infrastructure to ensure we maintain our local presence going forward."
The investment was aided by a $20 million bond issued by MassDevelopment, the first use of the Recovery Zone Facility Bond program in the state. The bond is one component of the American Recovery and Reinvestment Act to stimulate the economy with low-cost financing.
Pharmalucence produces eight drugs to treat cancers and heart disease. Construction on the new facility will begin this summer, and the plant is expected to be operational by the end of 2012.
Project Announcements
Ring Container Technologies Plans Whitestown, Indiana, Operations
09/17/2025
RK Industries Expands Aurora, Colorado, Headquarters Operations
09/17/2025
J.B. Hunt Transport Plans Tooele County, Utah, Operations
09/17/2025
Reser’s Fine Foods Expands Topeka, Kansas, Operations
09/16/2025
American Pacific Corporation Expands Iron County, Utah, Production Operations
09/15/2025
Swiss-Based Stadler Expands Salt Lake City, Utah, Operations
09/15/2025
Most Read
-
Tariffs, Talent, and U.S. Expansion
Q3 2025
-
What We’re Getting Wrong About Gen Z’s Future in the Skilled Trades
Q3 2025
-
Data Center Demand Stabilizes Amid Changing Market Forces
Q3 2025
-
Powering the Next Generation of Projects
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
A New Course for U.S. Shipbuilding
Q3 2025
-
Optimizing Your Rail-Served Transportation Network: Strategy Before Steel
Q2 2025